Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized study of Sepranolone (UC1010) in women with PMDD
2017-000822-37Phase 2Completed
- Sponsor
- Asarina Pharma AB
- Start
- Sep 2017
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sepranolone in Premenstrual Dysphoric Disorder (PMDD) (3 arms), sponsored by Asarina Pharma AB. Primary endpoint: Change from baseline in late luteal phase total symptom score (LmaxSum21). Started Sep 2017; status: completed.
02
Drugs
sepranolone
03
Conditions
Premenstrual Dysphoric Disorder (PMDD)
Beyond the preview
Go deeper on 2017-000822-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000822-37.